OGN stock holds steady on Organon’s general business focus

OGN stock is tied to Organon's women’s health and biosimilars business, with the shares listed on the New York Stock Exchange under the OGN ticker.

Organon & Co. (ISIN US68622V1061) is a New York Stock Exchange-listed healthcare company built around women’s health, biosimilars and established medicines. The stock trades under the OGN ticker and gives investors direct exposure to a diversified pharmaceutical cash-flow profile.

Business model

Organon focuses on branded medicines and products that usually sit outside the fastest-growing drug-launch cycle, which can make the company more dependent on execution, mix and margin discipline. That structure also makes the business easier to read than a broad pipeline-driven biotech story.

Market context

For US investors, Organon sits in the healthcare sector rather than the high-velocity growth pocket of the market. That means the stock is often assessed through earnings durability, leverage and portfolio quality more than through near-term product hype.

Women’s health focus

One representative part of the portfolio is Organon’s women’s health business, which remains central to the company’s identity and long-term revenue mix. That segment matters because it links the stock to recurring prescription demand rather than a single-product story.

Organon shares

Organon shares trade on the New York Stock Exchange under OGN. As of July 11, 2026, 10:00 a.m. ET, no live price was included in the available market data for this article.

Fact box

• Company: Organon & Co.
• ISIN: US68622V1061
• Ticker: OGN
• Exchange: New York Stock Exchange
• Sector / Industry: Healthcare / Pharmaceuticals
• Index membership: not yet officially scheduled
• Next earnings date: not yet officially scheduled